Barbara Sennino
Senior Vice President & Head, Early Development 3T Biosciences
Dr. Sennino is a seasoned expert in cancer immunotherapy, bringing over 15 years of experience from both academic institutions and biotechnology companies. She is currently serving as SVP of Early Development at 3T Biosciences where she oversees the development of T Cell Engagers. Before
joining 3T, she served as Vice President of Immunotherapy at Turnstone Biologics, leading the preclinical development of targeted tumor-infiltrating lymphocyte (TIL) programs. She has also held leadership roles at PACT Pharma, focusing on next-generation T cell receptor (TCR) therapies for solid
tumors, and contributed to Five Prime Therapeutics and Bavarian Nordic after completing her postdoctoral fellowship at the University of California, San Francisco. Dr. Sennino has published numerous articles in leading medical journals and holds several patents related to T cell therapies. She
earned her M.Sc. in Biology from Milan, Italy, and her Ph.D. in Biomedical Sciences from Brescia, Italy.
Seminars
To kick off, this industry leaders panel will discuss the computational x AI x biologics industry collaborations and advancements shaping the space over the last year, key challenges to be overcome, and identify the biggest opportunities based on industry trends.
- Taking a strategic SWOT analysis approach, what are the strengths, weaknesses, opportunities and threats to AI/ML-derived biologics?
- What advancements in AI/ML and computational tool convergence should we be most excited about when it comes to biologics design and optimization?
- What are the technical or scientific bottlenecks that are slowing down computational x AI x biologics design and optimization?
- Reflecting on the last year, what have been some of the most exciting industry collaborations that have given momentum to the computational x AI x biologics space?
- What can we learn from these collaborations in terms of where the space is heading?
- Using ML to integrate diverse datasets and map antigen prevalence across cancer and normal tissues
- Applying the 3T-TRACE platform to assess TCR and TCR-mimetic specificity and off-target cross-reactivity
- Engineering highly specific and safe T-cell engagers against shared targets for effective treatment of solid tumors
